PerformanceResearch Phase

IGF-1 DES (1-3)

Subcutaneous injection

Overview

IGF-1 DES (1-3) is a truncated analogue of insulin-like growth factor 1 lacking the first three N-terminal amino acids (glycine-proline-glutamate). This structural modification prevents binding to IGF binding proteins in serum, resulting in a shorter half-life but significantly increased potency at the IGF-1 receptor compared to native IGF-1.

Mechanism of Action

The peptide is hypothesized to promote localized muscle hypertrophy and tissue repair through enhanced receptor activation in target tissues..

Research Summary & Key Findings

No controlled clinical trials have been published in peer-reviewed journals. Evidence is limited to preclinical cell culture and animal models demonstrating increased myoblast proliferation and differentiation. This agent remains unregulated and its safety and efficacy in humans have not been established through formal investigation.

Clinical Status

Research Phase

IGF-1 DES (1-3) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Subcutaneous injection

Related Peptides in Performance

Find a Provider

Find a verified provider who offers IGF-1 DES (1-3) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply IGF-1 DES (1-3).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.